- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/535 - CSF du type granulocyteCSF du type granulocyte-macrophage
Détention brevets de la classe C07K 14/535
Brevets de cette classe: 680
Historique des publications depuis 10 ans
|
49
|
64
|
50
|
54
|
59
|
45
|
69
|
41
|
36
|
20
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Modernatx, Inc. | 1291 |
60 |
| Regeneron Pharmaceuticals, Inc. | 4698 |
18 |
| Institute for Research in Biomedicine (IRB) | 42 |
17 |
| Yale University | 2527 |
17 |
| Amgen Inc. | 4425 |
14 |
| Partner Therapeutics, Inc. | 28 |
13 |
| Children's Healthcare of Atlanta, Inc. | 262 |
12 |
| Emory University | 1719 |
12 |
| Replimune Limited | 41 |
12 |
| Elanco US Inc. | 718 |
11 |
| Ubiprotein, Corp. | 12 |
8 |
| The Jackson Laboratory | 368 |
7 |
| Xencor, Inc. | 412 |
7 |
| Ambrx, Inc. | 169 |
6 |
| Gradalis, Inc. | 54 |
6 |
| Hanmi Pharm. Co., Ltd. | 601 |
6 |
| Ningbo Innovative Mechanism Bioscience LLC | 7 |
6 |
| Ohio State Innovation Foundation | 2366 |
5 |
| The Regents of the University of Colorado, a body corporate | 2798 |
5 |
| Sandoz AG | 1412 |
4 |
| Autres propriétaires | 434 |